We provide you with 20 years of free, institutional-grade data for VECT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of VECT. Explore the full financial landscape of VECT stock.
| Reported Date | CIK | Ticker | Type |
|---|
VectivBio Holding AG Ordinary Shares(NASDAQ:VECT) 
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the tre...
Share this website to your friends
The information provided in this report about VECT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.